Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001213900-25-033316
Filing Date
2025-04-18
Accepted
2025-04-18 15:00:39
Documents
20
Period of Report
2025-06-02

Document Format Files

Seq Description Document Type Size
1 PROXY STATEMENT ea0237916-01.htm   iXBRL DEF 14A 1348140
6 GRAPHIC toruka_logo.jpg GRAPHIC 78491
7 GRAPHIC tproxy_001.jpg GRAPHIC 1059426
8 GRAPHIC tproxy_002.jpg GRAPHIC 1098054
  Complete submission text file 0001213900-25-033316.txt   8116372

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE orka-20250602.xsd EX-101.SCH 13456
3 XBRL DEFINITION FILE orka-20250602_def.xml EX-101.DEF 6760
4 XBRL LABEL FILE orka-20250602_lab.xml EX-101.LAB 43262
5 XBRL PRESENTATION FILE orka-20250602_pre.xml EX-101.PRE 11203
22 EXTRACTED XBRL INSTANCE DOCUMENT ea0237916-01_htm.xml XML 601983
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-22873 | Film No.: 25850257
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)